CTAD 2022 – gantenerumab’s shortcomings keep amyloid hypothesis alive
The failure of Roche’s Graduate 1 and 2 studies can be explained away by insufficient amyloid clearance.
CTAD 2022 – lecanemab data hold up, with a big but
Keenly awaited results reveal no smoking gun, but lecanemab’s modest activity appears not that different from Aduhelm’s.
When is big pharma no longer big pharma?
After a bruising few months for GSK, 17 global drug makers now have a higher market cap than the UK company.
Ash 2022 preview – Brukinsa has the edge over Calquence
Brukinsa’s head-to-head victory over Imbruvica is confirmed, and the Beigene BTK inhibitor looks better than Calquence too.
SABCS 2022 preview – now Arvinas’s degrader takes a knock
As all eyes turn to Astra’s camizestrant, a sneak peek at Arvinas’s data suggests that ARV-471 might not be competitive.
